ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO722

Glycemic Status and Mortality Among Patients with CKD

Session Information

Category: Diabetes

  • 502 Diabetes Mellitus and Obesity: Clinical


  • Rhee, Connie, University of California Irvine, Huntington Beach, California, United States
  • Kalantar-Zadeh, Kamyar, University of California Irvine, School of Medicine, Orange, California, United States
  • Ravel, Vanessa A., Harold Simmons Center, University of California at Irvine, Orange, California, United States
  • Brent, Gregory, VA Greater Los Angeles Healthcare, Los Angeles, California, United States
  • Nguyen, Danh V., University of California, Irvine, Irvine, California, United States
  • Streja, Elani, Harold Simmons Center for Kidney Disease Research and Epidemiology, Orange, California, United States
  • Kovesdy, Csaba P., University of Tennessee Health Science Center, Memphis, Tennessee, United States

There is uncertainty with regards to the optimal, precise glycemic level in diabetic non-dialysis dependent chronic kidney disease (NDD-CKD) patients. Whereas multiple studies show both lower and higher hemoglobin A1c (HbA1c) levels are associated with worse survival in diabetic dialysis patients, there are sparse data in NDD-CKD patients showing conflicting findings.


We examined the association of glycemic status, defined by baseline HbA1c, with all-cause mortality among US veterans with diabetes and Stage 3-5 NDD-CKD who underwent ≥1 HbA1c measure(s) over 2004-12 using expanded case-mix+laboratory Cox models. Sensitivity analyses incrementally adjusted for broad categories of anti-diabetic medications (insulin, oral medications) as well as specific categories (biguanides, thiazolidinediones, alpha-glucosidase inhibitors, insulin, insulin secretors, other oral medications).


Among 213,123 patients who met eligibility criteria, both lower HbA1c <6% and higher HbA1c ≥8% were associated with higher mortality (ref: 7-<8%): adjusted HRs (95% CI) 1.63 (1.47-1.81), 1.15 (1.12-1.18), 1.02 (0.99-1.04), 1.09 (1.05-1.13), 1.24 (1.18-1.30), 1.44 (1.38-1.51) for HbA1c <5, 5-<6, 6-<7, 8-<9, 9-<10, and ≥10%, respectively. This pattern of association was robust across analyses incrementally adjusted for broad and specific categories of anti-diabetic medications.


Among diabetic US veterans with NDD-CKD, there was a U-shaped association between HbA1c levels and mortality. Further studies are needed to determine whether treatment to a HbA1c target of 6-<8% improves survival in this population.